A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

Inclusion Criteria:

• Male or female, aged between 40 to 75;

• Subjects diagnosed with IPF according to guidelines for the diagnosis of idiopathicpulmonary fibrosis 2022 edition;

• Subjects with DLCO (measured/predicted value) ≥30% and <80%, and FVC (measured/predicted value) ≥50% within 3 months prior to screening

• Subjects tolerant to bronchofiberscope;

• Subjects tolerant to test of lung function;

• Subjects able to voluntarily sign the informed consent and cooperate with thecompletion of pulmonary function tests;

Exclusion Criteria:

• Female subject who is pregnant, nursing, or planning to be pregnant in half a yearafter using this product (or male subjects planning to have a pregnant spouse);

• At the time of screening, subject who is positive in each of treponema pallidumantibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surfaceantigen (HBsAg), hepatitis C virus (HCV) antibody test, except the following: (1)Hepatitis B virus carriers (only HBsAg positive, no hepatitis symptoms and signs,all liver function tests are normal); (2) Cured hepatitis C patients with negativeresult in HCV ribonucleic acid (RNA) test.

• Subject with malignant tumors or a history of malignant tumors;

• Subject with severe anemia, poorly controlled agranulocytosis and thrombocytopeniaat screening;

• Subject at risk of suicide or has a history of mental illness or epilepsy at thetime of screening;

• Subject with severe arrhythmias or atrioventricular block of degree II or above,shown by 12-lead Electrocardiogram (ECG);

• Subject who participated in other interventional clinical trials in the past 3months;

• Subject assessed as inappropriate to participate in this clinical trial byinvestigators.